IN VITRO INHIBITION OF BASOPHIL DEGRANULATION Aim of this test was to evaluate the capacity of Hi-Quercetin® to inhibit basophil degranulation. 3 Basophil degranulation is induced by specific allergens interacting with the IgE receptor located on the granulocyte surface. Basophil degranulation was compared to a positive benchmark (Hyaluronic Acid, HA) and b-hexaminidase was quantified as a marker of degranulation. Hi-Quercetin® resulted effective in a dose dependent way in inhibiting basophil degranulation up at a level of 83.6% (at a 10µg/ml), overcoming the performance of the positive benchmark. DID YOU KNOW... Quercetin is a powerful antioxidant, reported to be more potent than ascorbic acid and tocopherol. 6 It is also a powerful enzyme manipulator being a selective inhibitor of pro-inflammatory metabolites. 9 Also, it is one of the most abundant and ubiquitary secondary metabolites of the whole botanical kingdom, 7 where it also plays the role of a pigment to attract pollinators. 1.ISO/FDIS 16128-1, 2014. - 2. IARC Monographs, Vol 73, 1999. - 2. Abich report REL/533/2015/CLI/SAB, 2015. - 3. Abich report CLINICAL EFFICACY ON CHALLENGED SKIN 2 A single blind, placebo controlled human trial on 30 subjects has been conducted by inducing specific skin challenges causing redness, skin barrier disruption and allergic-like challenges following to the exposure to the following conditions: histamine(1%); UV irradiation; exfoliation induced by glycolic acid; skin barrier disruption induced by SLS. The Hi-Quercetin® soothing efficacy (in a 1% formulation) was tested at different times (according to the challenge model) and compared to the blank sample and a positive reference. In the histamine challenge, the wheal size was 13.25% smaller (p<0.001), even smaller than the positive benchmark. The redness following to UV challenge in the treated area was over 10% less intense compared to the placebo area (p<0.01). The SLS challenge has induced a skin barrier disruption evaluated by TEWL, and at 4 hours from the challenge and products application TEWL was 38.10% lower (p<0.001), overperforming the positive benchmark. Finally the challenge induced by glycolic acid, measured by Mexameter, decreased by almost 17% (p<0.0001). All other assessed parameters have been ameliorated, i. e. reported itch on the prick test, skin hydration, redness, in all challenges have been reported to significantly ameliorate skin conditions. Wheal size reduction following to prick test (histamine) % OF WHEAL SIZE REDUCTION (T30) 30 subjects Untreated Hi-Quercetin ® 140 130 120 110 100 90 30 min SKIN ANTIOXIDANT POWER % Skin antioxidant power 60 min 120 min 100 90 80 70 60 50 1.25 µg/ml % OF INHIBITION Inhibition of basophil degranulation 2.5 µg/ml 5 µg/ml 10 µg/ml * p<0.05 83.6% **p<0.001 ANTIOXIDANT CHALLENGE AND INHIBITION OF ROS Different tests aiming at the determination of the antioxidative efficacy of Hi- Quercetin® in cosmetic applications, were performed. The antioxidant capacity, reactivity, oxidation resistance and long term stability is to be evaluated with relevance to cosmetic formulations, skin intrinsic antioxidant capacity and ROS release inhibition. Determination of the Skin Antioxidative Protection (SAP): 4 Hi-Quercetin® was tested for its ability to permeate the epidermis and enhance the skin’s antioxidative defence system by 17% at the given concentration (0.5%) in a inert delivery system. It even overperformed the positive benchmark tocopherol (1%) by 125% (AUC). Determination of the Antioxidant Power (AP): 4 this in vitro standard diagnostic, benchmarked to vitamin C, has allowed to determine the antioxidative capacity and reactivity of Hi-Quercetin®. It has shown an antioxidant capacity that was fully maintained inside a cosmetic formulation (O/W emulsion) even after 48h at 40°C storage. Protective effect against UV induced oxidative stress: 5 when applied to a stabilized human keratinocytes cell line, Hi-Quercetin® was shown to significantly inhibit UVA induced ROS production al all tested dosages. Specifically, at the 0.05 mg/ml dosage and with the highest energy challenge (5J), ROS production was still reduced by 39.87%, overperforming by far ascorbic acid tested as positive benchmark. 10 min Hi-Quercetin®0.5% positive benchmark Tocopherol 1% placebo Placebo Positive control -14 -12 -10 -8 -6 -4 -2 ** T0 TEWL (g/h/m 2 ) TEWL variation from SLS challenge T60 T120 * *** p<0.0001 ** p<0.001 *p<0.01 80 75 70 65 60 55 50 45 40 35 30 untreated placebo Hi-Quercetin® positive benchmark ** *** *** 40 30 20 10 0 % OF INHIBITION OF ROS RELEASE Inhibition of UVA induced ROS release * p<0.05 Ascorbic acid 0.15 mg/ml 1J 3J 5J Hi-Quercetin® 1% emulsion 0.02 mg/ml Hi-Quercetin® 1% emulsion 0.05 mg/ml Hi-Quercetin® 1% emulsion 0.1 mg/ml ** Hi-Quercetin® positive benchmark (HA)
IN VITRO INHIBITION OF BASOPHIL DEGRANULATIONAim of this test
was to evaluate the capacity of Hi-Quercetin to inhibit basophil
degranulation.3 Basophil degranulation is induced by specific
allergens interacting with the IgE receptor located on the
granulocyte surface. Basophil degranulation was compared to a
positive benchmark (Hyaluronic Acid, HA) and b-hexaminidase was
quantified as a marker of degranulation. Hi-Quercetin resulted
effective in a dose dependent way in inhibiting basophil
degranulation up at a level of 83.6% (at a 10g/ml), overcoming the
performance of the positive benchmark.
DID YOU KNOW.. .Quercetin is a powerful antioxidant, reported to
be more potent than ascorbic acid and tocopherol. 6It is also a
powerful enzyme manipulator being a selective inhibitor of
pro-inflammatory metabolites. 9 Also, it is one of the most
abundant and ubiquitary secondary metabolites of the whole
botanical kingdom,7 where it also plays the role of a pigment to
attract pollinators.
CLINICAL EFFICACY ON CHALLENGED SKIN2A single blind, placebo
controlled human trial on 30 subjects has been conducted by
inducing specific skin challenges causing redness, skin barrier
disruption and allergic-like challenges following to the exposure
to the following conditions: histamine(1%); UV irradiation;
exfoliation induced by glycolic acid; skin barrier disruption
induced by SLS. The Hi-Quercetin soothing efficacy (in a 1%
formulation) was tested at different times (according to the
challenge model) and compared to the blank sample and a positive
reference. In the histamine challenge, the wheal size was 13.25%
smaller (p
